High-dose calcium channel blocker (CCB) shows strong blood pressure (BP) lowering effect. Currently available of controlled-release (CR) nifedipine 80 mg per day clinical data are limited to ...

ADALAT ® XL ® (nifedipine extended-release tablets) first received market authorization in Canada in 1995 and is indicated for the management of chronic stable angina and the management of mild to ...

Although a number of angiotensin receptor blocker (ARB)–CCB fixed-dose combinations are available, none have previously contained the extended-release formulation of nifedipine GITS. The potential ...

Nifedipine Tablets had U.S. sales of approximately $82 million for the 12 months ending June 30, 2010, according to IMS Health. Currently, Mylan has 161 ANDAs pending FDA approval representing $98.8 ...

Nifedipine Tablets had U.S. sales of approximately $234 million for the 12 months ending March 31, 2010, according to IMS Health. Currently, Mylan has 137 ANDAs pending FDA approval representing $94.9 ...

MUMBAI, Sept 16 (Reuters) - Matrix Laboratories has received U.S. FDA approval for nifedipine extended release tablets, the drug regulator's website showed on Thursday. Nifedipine tablets are used to ...

Watson Pharmaceuticals Inc has entered into a licensing and supply arrangement with Elan Corporation plc, whereby Watson has been granted exclusive United States rights to the 30mg and 60mg dosage ...

ADALAT® XL® (nifedipine extended-release tablets) first received market authorization in Canada in 1995 and is indicated for the management of chronic stable angina and the management of mild to ...

MISSISSAUGA, Ontario--(BUSINESS WIRE)-- Bayer Canada is pleased to announce a new partnership with Mint Pharmaceuticals Inc. for the distribution of ADALAT ® XL ® 30 mg tablets 1 in Canada. This ...